undisclosed dual HDAC6/10 inhibitor / Italfarmaco - LARVOL DELTA

Inhibiting both Class IIb HDACs is superior to isoform-specific inhibition for improved antitumor immune response. (AACR 2026) - "It is reported that HDAC6 inhibitors, Tubastatin A and Nexturastat A (NextA), inhibit both HDAC6 and HDAC10 isoforms with varying selectivity...In this study, we report novel HDAC inhibitors, ITF3756 and ITF6475, referred to as ITF3 and ITF6, respectively, and their effects on macrophage function and phenotype using murine bone marrow-derived Mφs (BMDMs), murine RAW264.7 cells, human PBMC-isolated monocyte-derived Mφs, and Thp1 monocyte-derived human Mφs...Finally, a combination of ITF3 with radiation therapy significantly suppressed Myc-Cap prostate cancer tumor growth while inducing an immune-stimulatory effect, as evidenced by increased infiltration of antitumor M1 Mφs and CD8 effector T cells. Overall, we demonstrated that dual HDAC6/10 inhibition is superior to HDAC6 inhibition alone for instigating an immunomodulatory antitumor immune response in prostate cancer therapy."

Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • CD8 • GLI2 • HDAC10